Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:142432108" >
Plasma Aβ42/40 rati...
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study
-
Perez-Grijalba, V (författare)
-
Arbizu, J (författare)
-
Romero, J (författare)
-
visa fler...
-
Prieto, E (författare)
-
Pesini, P (författare)
-
Sarasa, L (författare)
-
Guillen, F (författare)
-
Monleon, I (författare)
-
San-Jose, I (författare)
-
Martinez-Lage, P (författare)
-
Munuera, J (författare)
-
Hernandez, I (författare)
-
Buendia, M (författare)
-
Sotolongo-Grau, O (författare)
-
Alegret, M (författare)
-
Ruiz, A (författare)
-
Tarraga, L (författare)
-
Boada, M (författare)
-
Sarasa, M (författare)
-
Goni, M (författare)
-
Pujadas, F (författare)
-
Villarejo, A (författare)
-
Frank, A (författare)
-
Pena-Casanova, J (författare)
-
Fernandez, M (författare)
-
Pinol, G (författare)
-
Blesa, R (författare)
-
Gil, P (författare)
-
Pascual, LF (författare)
-
Aguilar, M (författare)
-
Frisoni, GB (författare)
-
Matias-Guiu, J (författare)
-
Andreasen, N (författare)
-
Antunez, C (författare)
-
visa färre...
- 2019-12-01
- 2019
- Engelska.
-
Ingår i: Alzheimer's research & therapy. - : Springer Science and Business Media LLC. - 1758-9193. ; 11:1, s. 96-
- Relaterad länk:
-
https://alzres.biome...
-
visa fler...
-
http://kipublication...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BackgroundTo facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer’s disease, supportive biomarker information is necessary. This study was aimed to investigate the association of plasma amyloid-beta (Aβ) levels with the presence of pathological accumulation of Aβ in the brain measured by amyloid-PET. Both plasma Aβ42/40 ratio alone or combined with an FDG-PET-based biomarker of neurodegeneration were assessed as potential AD biomarkers.MethodsWe included 39 cognitively normal subjects and 20 patients with mild cognitive impairment from the AB255 Study who had undergone PiB-PET scans. Total Aβ40 and Aβ42 levels in plasma (TP42/40) were quantified using ABtest kits. Subjects were dichotomized as Aβ-PET positive or negative, and the ability of TP42/40 to detect Aβ-PET positivity was assessed by logistic regression and receiver operating characteristic analyses. Combination of plasma Aβ biomarkers and FDG-PET was further assessed as an improvement for brain amyloidosis detection and diagnosis classification.ResultsEighteen (30.5%) subjects were Aβ-PET positive. TP42/40 ratio alone identified Aβ-PET status with an area under the curve (AUC) of 0.881 (95% confidence interval [CI] = 0.779–0.982). Discriminating performance of TP42/40 to detect Aβ-PET-positive subjects yielded sensitivity and specificity values at Youden’s cutoff of 77.8% and 87.5%, respectively, with a positive predictive value of 0.732 and negative predictive value of 0.900. All these parameters improved after adjusting the model for significant covariates. Applying TP42/40 as the first screening tool in a sequential diagnostic work-up would reduce the number of Aβ-PET scans by 64%. Combination of both FDG-PET scores and plasma Aβ biomarkers was found to be the most accurate Aβ-PET predictor, with an AUC of 0.965 (95% CI = 0.913–0.100).ConclusionsPlasma TP42/40 ratio showed a relevant and significant potential as a screening tool to identify brain Aβ positivity in preclinical and prodromal stages of Alzheimer’s disease.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Perez-Grijalba, ...
-
Arbizu, J
-
Romero, J
-
Prieto, E
-
Pesini, P
-
Sarasa, L
-
visa fler...
-
Guillen, F
-
Monleon, I
-
San-Jose, I
-
Martinez-Lage, P
-
Munuera, J
-
Hernandez, I
-
Buendia, M
-
Sotolongo-Grau, ...
-
Alegret, M
-
Ruiz, A
-
Tarraga, L
-
Boada, M
-
Sarasa, M
-
Goni, M
-
Pujadas, F
-
Villarejo, A
-
Frank, A
-
Pena-Casanova, J
-
Fernandez, M
-
Pinol, G
-
Blesa, R
-
Gil, P
-
Pascual, LF
-
Aguilar, M
-
Frisoni, GB
-
Matias-Guiu, J
-
Andreasen, N
-
Antunez, C
-
visa färre...
- Artiklar i publikationen
-
Alzheimer's rese ...
- Av lärosätet
-
Karolinska Institutet